Consumer Defensive
Live Price
Offline$18.88
+2.61% today
1Y Change
-37.36%
Window
Jun 23, 2025 → Jun 9, 2026
Coverage: 242 bars · Jun 23, 2025 → Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
USANA Health Sciences, Inc. (USNA) is a Consumer Defensive stock with a market cap of $360.00M and listed on NYSE. The stock last traded around $18.88 and down 37.4% across the available one-year price window (Jun 23, 2025 → Jun 9, 2026). Baseline metrics include revenue growth of +8.3%, EPS growth of -73.6%, a dividend yield of 0.0%. What stands out right now is revenue +8.3%, EPS -73.6%, free cash flow -83.3% with operating margin 5.5% and ROIC 2.2%. Valuation already assumes a fairly strong business story at P/E 32.9 and price/sales 0.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines USNA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Consumer Defensive peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
USNA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
USNA Max Drawdown
-52.30%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for USNA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.2B
+18.8% YoY
FY Net Income
$116.5M
+68.0% YoY
Free Cash Flow
$108.5M
+16.0% YoY
Revenue Growth
+8.3%
EPS Growth
-73.6%
Gross Margin
78.3%
Net Margin
1.2%
Income statement
USD
| Metric | 2026 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 925M | 855M | 921M | 999M | 1.2B |
| Gross Profit | 724M | 679M | 732M | 791M | 956M |
| Operating Income | 51M | 66M | 93M | 108M | 170M |
| EBITDA | 91M | 99M | 123M | 130M | 193M |
| Net Income | 11M | 42M | 64M | 69M | 117M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2026 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 158M | 182M | 330M | 288M | 240M |
| Total Assets | 743M | 748M | 633M | 597M | 578M |
| Total Liabilities | 157M | 162M | 136M | 162M | 183M |
| Shareholder Equity | 533M | 532M | 497M | 434M | 395M |
| Total Debt | 14M | 39M | 13M | 14M | 17M |
| Net Debt | -144M | -143M | -317M | -275M | -223M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
121M
+16.7% YoY
Capital Expenditures
13M
-22.7% YoY
Free Cash Flow
108M
+16.0% YoY
Key ratios
Gross Margin
78.3%
Operating Margin
5.5%
Net Margin
1.2%
ROE
2.0%
Debt / Equity
0.03x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.